N-Acetylcysteine (NAC) in Primary Sclerosing Cholangitis (PSC)
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07939841. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Proof-of-Principle Pilot Study of N-Acetylcysteine (NAC) Monotherapy to Assess Biochemical Changes in Primary Sclerosing Cholangitis (PSC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary sclerosing cholangitis (PSC) is a chronic disease that causes inflammation and scarring of the bile ducts and can lead to progressive liver damage. There are currently no approved medications that have been shown to improve long-term outcomes in patients with PSC. The purpose of this pilot study is to evaluate whether N-acetylcysteine (NAC), a medication that helps the body produce an antioxidant called glutathione, may improve liver blood tests in people with PSC. This is a single-center, open-label study involving approximately 15 adults with PSC. All participants will receive oral NAC at a dose of 1,200 mg per day for the first 12 weeks. At Week 12, the dose will either remain the same or increase to 1,800 mg per day, depending on changes in a liver blood test called alkaline phosphatase (ALP). Participants will continue treatment through Week 16. Those with a substantial improvement in ALP may be eligible to continue treatment through Week 20. Researchers will evaluate changes in liver blood tests, treatment safety, side effects, and medication adherence. Additional blood tests may help researchers better understand how NAC affects liver injury. This study is intended to provide preliminary information about the potential benefits and safety of NAC in PSC. It is not designed to establish whether NAC is an effective treatment for PSC.
Study identification
- NCT ID
- NCT07939841
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 5, 2026 (Estimated)
- Primary completion
- Jul 1, 2028 (Estimated)
- Completion
- Dec 1, 2028 (Estimated)
- Last update posted
- Nov 16, 2026
2026 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07939841, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 16, 2026 · Synced Nov 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.